Informations sur le produit
- (2E)-3-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-cyano-2-propenethioamide
- (2E)-3-amino-2-[(3,5-di-tert-butyl-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-3-sulfanylprop-2-enenitrile
- (3,5-Di-T-Butyl-4-Hydroxybenzylidene)Thiocyanoacetamide
- 2-Propenethioamide, 3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-cyano-, (2E)-
- 2-Propenethioamide, 3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-cyano-, (E)-
- Ag 879
- Alpha-Cyano-(3,5-Di-T-Butyl-4-Hydroxy)Thiocinnamide
- Alpha-Cyano-(3,5-Di-Tert-Butyl-4-Hydroxy)Thiocinnamamide
- Tyrphostin 879
- Α-Cyano-(3,5-Di-T-Butyl-4-Hydroxy)Thiocinnamide
- Voir d'autres synonymes
Tyrphostin AG 879 is a monoclonal antibody that binds to the extracellular domain of epidermal growth factor receptor 2. It is used as a diagnostic agent for the detection of fatty acid, peptide binding, and glycosidic bond. Tyrphostin AG 879 is also used for the treatment of cancer, in particular breast cancer. This antibody has been shown to activate pluripotent cells and promote the growth of tumor cells by blocking the epidermal growth factor receptor. Tyrphostin AG 879 has no effect on normal cells because it only activates receptors that are overexpressed in cancer cells.